About us

AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors

Our platforms will be clinically validated in two inherited retinal diseases: Usher1B and Stargardt disease. Our platforms may have the potential to be extended into many different disease areas where indications with a high unmet need are caused by a mutated large gene.

Our mission

Gene therapy based on adeno-associated viral (AAV) vectors has proven to be transformative in the treatment of genetic illnesses. However, the small DNA vector payload limits their further application. The AAVantgarde cutting-edge gene therapy technology platforms are focused on solving the constraint of oversized gene delivery, opening up the opportunity for genetic medicine delivery to more currently underserved patients with debilitating diseases.